Reports Q1 revenue $34.7M, consensus $32.97M. “We are extremely pleased with our ability to improve the financial efficiency of the business by growing revenues, improving margins, and reducing expenses. We made tremendous progress this quarter by promptly training CrossLink sales representatives and integrating them into our commercial execution, while also training our own commercial team on the newly expanded label for ZYNRELEF,” said Craig Collard, CEO.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRTX:
- Biotech Alert: Searches spiking for these stocks today
- Heron Therapeutics management to meet virtually with Northland
- Heron Therapeutics initiated with an Overweight at Capital One
- Heron Therapeutics Announces New Principal Accounting Officer
- Heron Therapeutics price target raised to $5 from $4 at Needham
